Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies
Top Cited Papers
- 1 May 2008
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (5) , 820-829
- https://doi.org/10.1111/j.1538-7836.2008.02939.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007
- Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor XaJournal of Medicinal Chemistry, 2007
- In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxabanJournal of Thrombosis and Haemostasis, 2007
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Exosite-driven substrate specificity and function in coagulationJournal of Thrombosis and Haemostasis, 2005
- Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agentExpert Opinion on Investigational Drugs, 2002
- Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in RabbitsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Orally Active Isoxazoline GPIIb/IIIa AntagonistsCardiovascular Drug Reviews, 1998
- Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitorThrombosis Research, 1995
- [18] Purification of human coagulation factors II, IX, and X using sulfated dextran beadsPublished by Elsevier ,1981